• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by AcelRx Pharmaceuticals Inc. (Amendment)

    1/27/22 2:51:06 PM ET
    $ACRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACRX alert in real time by email
    SC 13G/A 1 doc1.htm NONE Schedule 13G


     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 2)*
     
    ACELRX PHARMACEUTICALS, INC. 

    (Name of Issuer)
     
    Common Stock

    (Title of Class of Securities)
     
    00444T100

    (CUSIP Number)
     
    Calendar Year 2021

    (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
         o  Rule 13d-1(b)
     
         x  Rule 13d-1(c)
     
         o  Rule 13d-1(d)
     
    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
     
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     


     
     

     
     
    CUSIP No.  00444T100      
     
          
    1 NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
     BML Investment Partners, L.P.
       
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a)   o
     (b)   x
       
    3 SEC USE ONLY
      
      
       
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
      
     Delaware
        
    NUMBER OF SHARES BENEFICIALLY  OWNED BY EACH REPORTING PERSON WITH: 5 SOLE VOTING POWER
      
     0
       
    6 SHARED VOTING POWER
      
     0
       
    7 SOLE DISPOSITIVE POWER
      
     0
       
    8 SHARED DISPOSITIVE POWER
      
     0
       
    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
      
     0
       
    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      
     o
       
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
      
     0.0%
       
    12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
      
     PN
     

    FOOTNOTES
      
     BML Investment Partners, L.P. is a Delaware limited partnership whose sole general partner is BML Capital Management, LLC. The managing member of BML Capital Management, LLC is Braden M. Leonard. As a result, Braden M. Leonard is deemed to be the indirect owner of the shares held directly by BML Investment Partners, L.P. Despite such shared beneficial ownership, the reporting persons disclaim that they constitute a statutory group within the meaning of Rule 13d-5(b)(1) of the Exchange Act.
     
     

     
     
    CUSIP No.  00444T100      
     
          
    1 NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
     Braden M Leonard
       
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a)   o
     (b)   x
       
    3 SEC USE ONLY
      
      
       
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
      
     United States
        
    NUMBER OF SHARES BENEFICIALLY  OWNED BY EACH REPORTING PERSON WITH: 5 SOLE VOTING POWER
      
     0
       
    6 SHARED VOTING POWER
      
     0
       
    7 SOLE DISPOSITIVE POWER
      
     0
       
    8 SHARED DISPOSITIVE POWER
      
     0
       
    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
      
     0
       
    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      
     o
       
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
      
     0%
       
    12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
      
     IN
     

    FOOTNOTES
      
     BML Investment Partners, L.P. is a Delaware limited partnership whose sole general partner is BML Capital Management, LLC. The managing member of BML Capital Management, LLC is Braden M. Leonard. As a result, Braden M. Leonard is deemed to be the indirect owner of the shares held directly by BML Investment Partners, L.P. Despite such shared beneficial ownership, the reporting persons disclaim that they constitute a statutory group within the meaning of Rule 13d-5(b)(1) of the Exchange Act
     
     

     
     
    Item 1.

     
    (a)
    Name of Issuer
     
     
    ACELRX PHARMACEUTICALS, INC.

     
    (b)
    Address of Issuer’s Principal Executive Offices
     
     
    351 Galveston Drive

    Redwood City, CA 94063

    Item 2.

     
    (a)
    Name of Person Filing
     
     
    BML Investment Partners, L.P.

     
    (b)
    Address of Principal Business Office or, if none, Residence
     
     
    65 E Cedar - Suite 2
    Zionsville, IN 46077

     
    (c)
    Citizenship
     
     
    Delaware

     
    (d)
    Title of Class of Securities
     
     
    Common Stock

     
    (e)
    CUSIP Number
     
     
    00444T100

     
    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     
    (a)
    o
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     
    (b)
    o
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     
    (c)
    o
    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     
    (d)
    o
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

     
    (e)
    o
    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     
    (f)
    o
    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     
    (g)
    o
    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     
    (h)
    o
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     
    (i)
    o
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     
    (j)
    o
    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J).

     
    (k)
    o
    A group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     
     
     

     
     
    Item 4.
    Ownership.
     
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     
    (a)
    Amount beneficially owned: 0

     
    (b)
    Percent of class: 0.0%

     
    (c)
    Number of shares as to which the person has:

     
    (i)
    Sole power to vote or to direct the vote: 0

     
    (ii)
    Shared power to vote or to direct the vote: 0

     
    (iii)
    Sole power to dispose or to direct the disposition of: 0

     
    (iv)
    Shared power to dispose or to direct the disposition of: 0

    Item 5.
    Ownership of Five Percent or Less of a Class
     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x .
     
     
     
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.
     
    N/A
     
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
     
    N/A
     
    Item 8.
    Identification and Classification of Members of the Group
     
    N/A
     
    Item 9.
    Notice of Dissolution of Group
     
    N/A
     
     
     

     
     
     
    Item 10.
    Certification
      
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.
     
     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
     
     BML Capital Management, LLC
     
        
    Date: January 27, 2022
    By:
    /s/  Braden M Leonard 
       Name: Braden M Leonard 
       Title:  Managing Member 
        
     
     
     
      
        
    Date: January 27, 2022
    By:
    /s/  Braden M Leonard 
       Name: Braden M Leonard 
       
        
     
    Footnotes:
    BML Investment Partners, L.P. is a Delaware limited partnership whose sole general partner is BML Capital Management, LLC. The managing member of BML Capital Management, LLC is Braden M.Leonard. As a result, Braden M.Leonard is deemed to be the indirect owner of the shares held directly by BML Investment Partners, L.P. Despite such shared beneficial ownership, the reporting persons disclaim that they constitute a statutory group within the meaning of Rule 13d-5(b) (1) of the Exchange Act.

    Attention:
    Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)
     
     


    Get the next $ACRX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ACRX

    DatePrice TargetRatingAnalyst
    8/17/2021$7.00 → $5.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $ACRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Angotti Vincent J. bought $7,268 worth of shares (10,000 units at $0.73), increasing direct ownership by 11% to 101,805 units (SEC Form 4)

      4 - ACELRX PHARMACEUTICALS INC (0001427925) (Issuer)

      12/14/23 8:11:04 AM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AcelRx Announces Rebranding With Name Change to Talphera, Inc.

      Name change to "Talphera" reflects a new era of the Company in partnership with the medical community developing novel solutions for medically supervised settings Talphera will begin trading on Nasdaq under the trading symbol "TLPH" effective January 10 SAN MATEO, Calif., Jan. 9, 2024 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the rebranding of the Company, with a name change to Talphera, Inc. ("Talphera"). The rebrand decision was made to reflect the Company's strategy of developing and commercializin

      1/9/24 9:05:00 AM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States

      Use of CRRT increased during COVID and remained at these higher utilization levels Study results demonstrate challenges physicians have with heparin and citrate, the two currently available CRRT anticoagulants  SAN MATEO, Calif., Dec. 12, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the publication of a quantitative market research study evaluating current U.S. physician anticoagulation use during continuous renal replacement therapy (CRRT) in patients with acute kidney injury in the intensive care unit.  Th

      12/12/23 8:30:00 AM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AcelRx Receives IDE Approval for Niyad and Advances to a Single Registration Study

       Investigational Device Exemption (IDE) approval by the U.S. Food and Drug Administration (FDA) allows AcelRx to begin pivotal study of Niyad™ Single registration study with pre-agreed upon endpoints planned to initiate in Q4 2023 with topline data expected mid-2024; clinical site readiness is currently underway Niyad would be the first and only approved regional anticoagulant in the U.S. for the extracorporeal circuit, if approved by the FDA SAN MATEO, Calif., Oct. 3, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, t

      10/3/23 8:30:00 AM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRX
    SEC Filings

    See more
    • SEC Form EFFECT filed by AcelRx Pharmaceuticals Inc.

      EFFECT - TALPHERA, INC. (0001427925) (Filer)

      2/14/24 12:15:23 AM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B7 filed by AcelRx Pharmaceuticals Inc.

      424B7 - TALPHERA, INC. (0001427925) (Filer)

      2/13/24 4:27:26 PM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-3 filed by AcelRx Pharmaceuticals Inc.

      S-3 - TALPHERA, INC. (0001427925) (Filer)

      2/6/24 4:44:41 PM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on AcelRx Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of AcelRx Pharmaceuticals with a rating of Buy and set a new price target of $5.00 from $7.00 previously

      8/17/21 6:22:04 AM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Dasu Badri N covered exercise/tax liability with 1,618 shares, decreasing direct ownership by 9% to 17,153 units (SEC Form 4)

      4 - TALPHERA, INC. (0001427925) (Issuer)

      2/13/24 9:46:15 PM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Palmer Pamela P covered exercise/tax liability with 1,602 shares, decreasing direct ownership by 4% to 35,344 units (SEC Form 4)

      4 - TALPHERA, INC. (0001427925) (Issuer)

      2/13/24 9:44:54 PM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Asadorian Raffi covered exercise/tax liability with 1,790 shares, decreasing direct ownership by 8% to 20,291 units (SEC Form 4)

      4 - TALPHERA, INC. (0001427925) (Issuer)

      2/13/24 9:42:43 PM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRX
    Leadership Updates

    Live Leadership Updates

    See more
    • AcelRx Pharmaceuticals Announces the Appointment of Jill Broadfoot to its Board of Directors

      HAYWARD, Calif., Nov. 23, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the appointment of Jill Broadfoot to the company's Board of Directors. Ms. Broadfoot currently serves as the Chief Financial Officer (CFO) of aTyr Pharma, Inc., a position she has held since July 2018. Prior to joining aTyr, Ms. Broadfoot served as CFO of Emerald Health Pharmaceuticals and Emerald Health Bioceuticals, where she was responsible for establishing operations for the U.S.-based pharmaceutical and bioceutical entities as well as

      11/23/21 5:09:00 PM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adamis Announces Appointment of Meera Desai, Ph.D., to Board of Directors

      SAN DIEGO, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today announced the appointment of Meera J. Desai, Ph.D., as a new director and member of the company's board of directors. Dr. Desai replaces Roshawn Blunt, who retired from the Board effective October 1, 2021. Richard Williams, Chairman of the Board, commented: "We are pleased to welcome Dr. Desai to the Board and look forward to working with her to pursue long-term value creation. Her substantial expertise in international pharmaceutical licensing, combined with her background in drug development and commercialization will help us refine corporate strategy to maximize our product pipeline. I

      10/4/21 7:30:00 AM ET
      $ACRX
      $ADMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AcelRx Pharmaceuticals Announces Appointment of Marina Bozilenko to the Board of Directors

      REDWOOD CITY, Calif., March 31, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the appointment of Marina Bozilenko as an independent member of the company's Board of Directors. Ms. Bozilenko has over 30 years of investment banking and other healthcare industry experience, including raising more than $30 billion in capital and executing numerous M&A transactions. She currently serves as a strategic advisor to William Blair & Company, a firm she joined in 2010 as head of biotech & pharma and managing director.

      3/31/21 8:30:00 AM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRX
    Financials

    Live finance-specific insights

    See more
    • AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate Update

      Capital raise closed in July, led by new healthcare investors; provides access to up to $26.3 million in capital, with $10 million immediately available AcelRx awaits response to Emergency Use Authorization (EUA) of Niyad™ submitted to the FDA in April; registrational study set to initiate in Q4 2023 Proforma $17.4 million in cash as of June 30, 2023, including gross proceeds from financing closed in July 2023 Senior debt with Oxford fully repaid in Q2 2023 Webcast and conference call to be held today at 4:30 p.m. EDT SAN MATEO, Calif., Aug. 10, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commer

      8/10/23 4:05:00 PM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AcelRx to Host Second Quarter 2023 Financial Results Call and Webcast on August 10, 2023

      HAYWARD, Calif., July 27, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release second quarter 2023 financial results after market close on Thursday, August 10, 2023, then host a live webcast and conference call at 4:30 p.m. Eastern Daylight Time/1:30 p.m. Pacific Daylight Time to discuss the results and provide an update on the Company's business.   Webcast Information The webcast can be accessed here or by visiting the Investors section of the Company's website at www.acelrx.com and cl

      7/27/23 4:05:00 PM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

      Request for Emergency Use Authorization of Niyad™ submitted to the FDA in April Divestment of DSUVIA® to Alora Pharmaceuticals closed April 3, 2023 $13.4 million in cash as of March 31, 2023 Webcast and conference call to be held today at 4:30 p.m. EDT HAYWARD, Calif., May 10, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its first quarter 2023 financial results and provided a corporate update. "We have embarked on a new AcelRx chapter by closing the DSUVIA transaction and submitting the request for a

      5/10/23 4:05:00 PM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by AcelRx Pharmaceuticals Inc. (Amendment)

      SC 13G/A - TALPHERA, INC. (0001427925) (Subject)

      2/14/24 2:58:44 PM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by AcelRx Pharmaceuticals Inc. (Amendment)

      SC 13G/A - TALPHERA, INC. (0001427925) (Subject)

      2/13/24 8:00:48 PM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by AcelRx Pharmaceuticals Inc.

      SC 13D - TALPHERA, INC. (0001427925) (Subject)

      1/22/24 6:46:08 PM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care